Abstract
The medical treatment for patients with stable angina rests in correcting risk factors predisposing to the progression of coronary heart disease and unstable coronary artery plaques. High importance should be given to lowering low-density lipoprotein values as far below 100 mg/dl as possible with diet and medication, usually a statin. Control of blood pressure, blood sugar, and heart rate are very important. Medications that reduce myocardial oxygen demand (beta blockers) and those that increase myocardial blood flow (nitrates and selected calcium antagonists in appropriate patients) are sometimes also important. Aspirin therapy to reduce risk of intracoronary thrombus formation and possibly attenuate inflammation is also important in all patients who are able to take it. The patient on ideal medical therapy with angina or objective evidence of myocardial ischemia at rest or low levels of effort should undergo coronary arteriography with a plan to proceed to percutaneous coronary intervention or coronary artery surgery when the coronary anatomy allows. Patients with heart failure and stable angina need to be evaluated similarly with imaging procedures that characterize their left ventricular function, cardiac valves, and pulmonary artery pressure.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Danahy DT, Aronow WS. Hemodynamics and antianginal effects of high dose oral isosorbide dinitrate after chronic use. Circulation. 1977;56(2):205–12.
Glancy DL, Richter MA, Ellis EV, Johnson W. Effect of swallowed isosorbide dinitrate on blood pressure, heart rate and exercise capacity in patients with coronary artery disease. Am J Med. 1977;62(1):39–46.
Horowitz JD, Antman EM, Lorell BH, Barry WH, Smith TW. Potentiation of the cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation. 1983;68(6):1247–53.
Markis JE, Gorlin R, Mills RM, et al. Sustained effect of orally administered isosorbide dinitrate on exercise performance of patients with angina pectoris. Am J Cardiol. 1979;43(2):265–71.
Mason DT, Braunwald E. The effects of nitroglycerin and amyl nitrite on arteriolar and venous tone in the human forearm. Circulation. 1965;32(5):755–66.
Murad F, Arnold WP, Mittal CK, Braughler JM. Properties and regulation of guanylate cyclase and some proposed functions for cyclic GMP. Adv Cyclic Nucleotide Res. 1979;11:175–204.
Parker JO, VanKoughnett KA, Fung HL. Transdermal isosorbide dinitrate in angina pectoris: effect of acute and sustained therapy. Am J Cardiol. 1984;54(1):8–13.
Reichek N, Priest C, Zimrin D, Chandler T, Sutton MS. Antianginal effects of nitroglycerin patches. Am J Cardiol. 1984;54(1):1–7.
Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action an dose-response relation during acute and sustained therapy. Am J Cardiol. 1982;49(2):411–9.
Abrams J. Nitrate tolerance and dependence. Am Heart J. 1980;99(1):113–23.
Needleman P, Johnson Jr EM. Mechanism of tolerance development to organic nitrates. J Pharmacol Exp Ther. 1973;184(3):709–15.
Cheitlin MD, Hutter Jr AM, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;33(1):273–82.
Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560–72.
Smith Jr SC, Blair SN, Bonow RO, et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol. 2001;38(5):1581–3.
Conolly ME, Kersting F, Dollery CT. The clinical pharmacology of beta-adrenoceptor-blocking drugs. Prog Cardiovasc Dis. 1976;19(3):203–34.
Dreyfuss J, Brannick LJ, Vukovich RA, Shaw JM, Willard DA. Metabolic studies in patients with nadolol: oral and intravenous administration. J Clin Pharmacol. 1977;17(5–6):300–7.
Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 1. Pharmacodynamic and pharmacokinetic properties. Am Heart J. 1979;97(5):663–70.
Frishman W. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 9. Nadolol: a new long-acting beta-adrenoceptor blocking drug. Am Heart J. 1980;99(1):124–8.
Koch-Weser J. Drug therapy: metoprolol. N Engl J Med. 1979;301(13):698–703.
Koch-Weser J, Frishman WH. beta-Adrenoceptor antagonists: new drugs and new indications. N Engl J Med. 1981;305(9):500–6.
Moses JW, Borer JS. Beta-adrenergic antagonists in the treatment of patients with heart disease. Dis Mon. 1981;27(9):1–61.
Opie LH. Drugs and the heart. Lancet. 1980;1(8170):693–8.
Andreasen F, Boye E, Christoffersen E, et al. Assessment of verapamil in the treatment of angina pectoris. Eur J Cardiol. 1975;2(4):443–52.
Balasubramanian V, Khanna PK, Naryanan GR, Hoon RS. Verapamil in ischaemic heart disease – quantitative assessment by serial multistage treadmill exercise. Postgrad Med J. 1976;52(605):143–7.
Forman R, Eng C, Kirk ES. Comparative effect of verapamil and nitroglycerin on collateral blood flow. Circulation. 1983;67(6):1200–4.
Freedman B, Dunn RF, Richmond DR, Kelly DT. Coronary artery spasm during exercise: treatment with verapamil. Circulation. 1981;64(1):68–75.
Gunther S, Green L, Muller JE, Mudge Jr GH, Grossman W. Prevention of nifedipine of abnormal coronary vasoconstriction in patients with coronary artery disease. Circulation. 1981;63(4):849–55.
Hansen JF, Sandoe E. Treatment of Prinzmetal’s angina due to coronary artery spasm using verapamil: a report of three cases. Eur J Cardiol. 1978;7(4):327–35.
Heng MK, Singh BN, Roche AH, Norris RM, Mercer CJ. Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram. Am Heart J. 1975;90(4):487–98.
Hillis LD. The new coronary vasodilators: calcium blockers. J Cardiovasc Med. 1980;5(6):583–90.
Hugenholtz PG, Michels HR, Serruys PW, Brower RW. Nifedipine in the treatment of unstable angina, coronary spasm and myocardial ischemia. Am J Cardiol. 1981;47(1):163–73.
Johnson SM, Mauritson DR, Corbett JR, et al. Double-blind, randomized, placebo-controlled comparison of propranolol and verapamil in the treatment of patients with stable angina pectoris. Am J Med. 1981;71(3):443–51.
Johnson SM, Mauritson DR, Willerson JT, Hillis LD. A controlled trial of verapamil for Prinzmetal’s variant angina. N Engl J Med. 1981;304(15):862–6.
Johnson SM, Mauritson DR, Willerson JT, Hillis LD. Comparison of verapamil and nifedipine in the treatment of variant angina pectoris: preliminary observations in 10 patients. Am J Cardiol. 1981;47(6):1295–300.
Livesley B, Catley PF, Campbell RC, Oram S. Double-blind evaluation of verapamil, propranolol, and isosorbide dinitrate against a placebo in the treatment of angina pectoris. Br Med J. 1973;1(5850):375–8.
Muller JE, Gunther SJ. Nifedipine therapy for Prinzmetal’s angina. Circulation. 1978;57(1):137–9.
Nagao T, Ikeo T, Sato M. Influence of calcium ions on responses to diltiazem in coronary arteries. Jpn J Pharmacol. 1977;27(2):330–2.
Neumann M, Luisada AA. Double blind evaluation of orally administered iproveratril in patients with angina pectoris. Am J Med Sci. 1966;251(5):552–6.
Previtali M, Salerno JA, Tavazzi L, et al. Treatment of angina at rest with nifedipine: a short-term controlled study. Am J Cardiol. 1980;45(4):825–30.
Sandler G, Clayton GA, Thornicroft SG. Clinical evaluation of verapamil in angina pectoris. Br Med J. 1968;3(5612):224–7.
Schamroth L. Immediate effects of intravenous verapamil on atrial fibrillation. Cardiovasc Res. 1971;5(4):419–24.
Schroeder JS, Lamb IH, Ginsburg R, Bristow MR, Hung J. Diltiazem for long-term therapy of coronary arterial spasm. Am J Cardiol. 1982;49(3):533–7.
Solberg LE, Nissen RG, Vlietstra RE, Callahan JA. Prinzmetal’s variant angina – response to verapamil. Mayo Clin Proc. 1978;53(4):256–9.
Theroux P, Waters DD, Affaki GS, et al. Provocative testing with ergonovine to evaluate the efficacy of treatment with calcium antagonists in variant angina. Circulation. 1979;60(3):504–10.
Weishaar R, Ashikawa K, Bing RJ. Effect of diltiazem, a calcium antagonist, on myocardial ischemia. Am J Cardiol. 1979;43(6):1137–43.
Winniford MD, Johnson SM, Mauritson DR, et al. Verapamil therapy for Prinzmetal’s variant angina: comparison with placebo and nifedipine. Am J Cardiol. 1982;50(4):913–8.
Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–25.
Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation. 1995;92(5):1326–31.
Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94(3):258–65.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342(3):145–53.
Fox KM, Henderson JR, Bertrand ME, et al. The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur Heart J. 1998;19(Suppl J):J52–5.
Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058–68.
Eidt JF, Allison P, Noble S, et al. Thrombin is an important mediator of platelet aggregation in stenosed canine coronary arteries with endothelial injury. J Clin Invest. 1989;84(1):18–27.
Eidt JF, Ashton J, Golino P, et al. Thromboxane A2 and serotonin mediate coronary blood flow reductions in unsedated dogs. Am J Physiol. 1989;257(3 Pt 2):H873–82.
Golino P, Ambrosio G, Ragni M, et al. Short-term and long-term role of platelet activating factor as a mediator of in vivo platelet aggregation. Circulation. 1993;88(3):1205–14.
Golino P, Piscione F, Benedict CR, et al. Local effect of serotonin released during coronary angioplasty. N Engl J Med. 1994;330(8):523–8.
Yao SK, Ober JC, Ferguson JJ, et al. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation. 1992;86(6):1993–9.
Yao SK, Ober JC, Gonenne A, et al. Active oxygen species play a role in mediating platelet aggregation and cyclic flow variations in severely stenosed and endothelium-injured coronary arteries. Circ Res. 1993;73(5):952–67.
Yao SK, Ober JC, McNatt J, et al. ADP plays an important role in mediating platelet aggregation and cyclic flow variations in vivo in stenosed and endothelium-injured canine coronary arteries. Circ Res. 1992;70(1):39–48.
Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J. 1988;296(6618):320–31.
Steering Committee of the Physicians’ Health Study Research Group. Final report on the aspirin component of the ongoing Physicians’ Health Study. N Engl J Med. 1989;321(3):129–35.
Klimt CR, Knatterud GL, Stamler J, Meier P. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol. 1986;7(2):251–69.
Peto R, Gray R, Collins R, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J. 1988;296(6618):313–6.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308(6921):81–106.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy – II: maintenance of vascular graft or arterial patency by antiplatelet therapy. BMJ. 1994;308(6922):159–68.
Antiplatelet Trialists’ Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ. 1994;308(6923):235–46.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.
Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet. 1999;353(9171):2179–84.
Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342(24):1773–7.
Ferguson J. Clopidogrel. In: Braunwald E, editor. Harrison’s advances in cardiology. New York: McGraw-Hill; 2002. p. 144–54.
Kupfer Y, Tessler S. Ticlopidine and thrombotic thrombocytopenic purpura. N Engl J Med. 1997;337(17):1245.
Pereillo JM, Maftouh M, Andrieu A, et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos. 2002;30(11):1288–95.
Savi P, Pereillo JM, Uzabiaga MF, et al. Identification and biological activity of the active metabolite of clopidogrel. Thromb Haemost. 2000;84(5):891–6.
Schror K. The basic pharmacology of ticlopidine and clopidogrel. Platelets. 1993;4(5):252–61.
Schror K. Ticlopidine and clopidogrel. In: Ferguson J, Chronos NAF, Harrington RA, editors. Antiplatelet therapy in clinical practice. London: Martin Duntz; 2000. p. 93–113.
Weber AA, Reimann S, Schror K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol. 1999;126(2):415–20.
Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989;1(8649):1215–20.
Hass WK, Easton JD, Adams Jr HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med. 1989;321(8):501–7.
CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–39.
Bhatt DL, Chew DP, Hirsch AT, et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001;103(3):363–8.
Bhatt DL, Marso SP, Hirsch AT, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90(6):625–8.
Ferguson J, Massin EK. The effect of clopidogrel vs. aspirin on recurrent clinical events and mortality: results from the CAPRIE study. J Am Coll Cardiol. 2001;37(2 Suppl A):36A.
Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494–502.
Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358(9281):527–33.
Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354(16):1706–17.
Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116(25):2923–32.
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.
Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120(25):2577–85.
Gurbel PA, Bliden KP, Butler K, et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010;121(10):1188–99.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial. The SYMPHONY Investigators. Sibrafiban versus Aspirin to Yield Maximum Protection from Ischemic Heart Events Post-acute Coronary Syndromes. Lancet. 2000;355(9201):337–45.
Second SYMPHONY Investigators. Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. Circulation. 2001;103(13):1727–33.
O’Neill WW, Serruys P, Knudtson M, et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators Evaluation of Oral Xemilofiban in Controlling Thrombotic Events. N Engl J Med. 2000;342(18):1316–24.
Topol EJ, Easton D, Harrington RA, et al. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108(4):399–406.
Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation. 2001;103(2):201–6.
Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107(12):1692–711.
Whitlon DS, Sadowski JA, Suttie JW. Mechanism of coumarin action: significance of vitamin K epoxide reductase inhibition. Biochemistry (Mosc). 1978;17(8):1371–7.
The Medical Research Council’s General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet. 1998;351(9098):233–41.
Chalmers TC, Matta RJ, Smith Jr H, Kunzler AM. Evidence favoring the use of anticoagulants in the hospital phase of acute myocardial infarction. N Engl J Med. 1977;297(20):1091–6.
Greisman H, Marcus RM. Acute myocardial infarction; detailed study of dicumarol therapy in 75 consecutive cases. Am Heart J. 1948;36(4):600–9.
Smith FJ, Keyes JW, Denham RM. Myocardial infarction: a study of the acute phase in 920 patients. Am J Med Sci. 1951;221(5):508–21.
Furman RH, Ball CO, Gale RG, Billings Jr FT, Meneely GR. An evaluation of anticoagulant therapy in myocardial infarction based on prognostic categories. Am J Med. 1953;14(6):681–8.
Loudon IS, Pease JC, Cooke AM. Anticoagulants in myocardial infarction. Br Med J. 1953;1(4816):911–3.
Schnur S. Mortality and other studies questioning the evidence for and value of routine anticoagulant therapy in acute myocardial infarction. Circulation. 1953;7(6):855–68.
Burton CR. Anticoagulant therapy of recent cardiac infarction. Can Med Assoc J. 1954;70(4):404–8.
Manson DI, Fullerton HW. Anticoagulant therapy in cardiac infarction. Br Med J. 1956;1(4957):6–8.
Eastman GL, Cook ET, Shinn ET, Dutton RE, Lyons RH. A clinical study of anticoagulants in acute myocardial infarction with particular reference to early heparin therapy. Am J Med Sci. 1957;233(6):647–53.
Honey GE, Truelove SC. Prognostic factors in myocardial infarction. Lancet. 1957;272(6980):1155–61; contd.
Honey GE, Truelove SC. Prognostic factors in myocardial infarction. Lancet. 1957;272(6981):1209–12.
Rosenberg BA, Malach M. Acute myocardial infarction in a city hospital. II. Experience with anticoagulants. Am J Cardiol. 1958;2(1):71–80.
Toohey M. Anticoagulants in myocardial infarction. Br Med J. 1958;1(5065):252–5.
Richards RL, Seaton DA. Further observations on the value of anticoagulant therapy in the treatment of acute myocardial infarction. Scott Med J. 1961;6:559–64.
Blake TM, Orr ER, Simmons JW. Ineffectiveness of anticoagulants in myocardial infarction. Am Heart J. 1962;63:462–5.
Griffith GC, Leak D, Hegde B. Conservative anticoagulant therapy of acute myocardial infarction. Ann Intern Med. 1962;57:254–65.
Gumpert TE. Anticoagulant treatment in 104 male cases of acute myocardial infarction. Lancet. 1962;1(7226):399–400.
Meltzer LE, Palmon F, Ferrigan M, et al. Prothrombin levels and fatality rates in acute myocardial infarction. JAMA. 1964;187:986–93.
Modan B, Shani M, Schor S, Modan M. Reduction of hospital mortality from acute myocardial infarction by anticoagulant therapy. N Engl J Med. 1975;292(26):1359–62.
Tonascia J, Gordis L, Schmerler H. Retrospective evidence favoring use of anticoagulants for myocardial infarctions. N Engl J Med. 1975;292(26):1362–6.
Wright IS, Marple CD, Beck DF. Report of the Committee for the Evaluation of Anticoagulants in the Treatment of Coronary Thrombosis with Myocardial Infarction; a progress report on the statistical analysis of the first 800 cases studied by this committee. Am Heart J. 1948;36(6):801–15.
Bresnick E, Selverstone LA, Rapoport B, et al. Experiences with dicumarol in acute myocardial infarction. N Engl J Med. 1950;243(21):806–10.
Tulloch JA, Gilchrist AR. Anticoagulants in treatment of coronary thrombosis. Br Med J. 1950;2(4686):965–71.
Holten C. Anticoagulants in the treatment of coronary thrombosis. Acta Med Scand. 1951;140(5):340–8.
Feldman L, O’Connor WR, Friedman IA, Fischer JW. Anticoagulant therapy in acute myocardial infarction. Am Heart J. 1952;44(1):112–8.
Rashkoff IA, Schaefer LE, Magida MG, Levy H. Evaluation of dicumarol therapy in 287 cases of acute myocardial infarction. J Mt Sinai Hosp N Y. 1952;18(6):350–7.
McCluskie JA, Seaton DA. The value of anticoagulant therapy in the treatment of acute myocardial infarction. Scott Med J. 1959;4(6):305–9.
Hilden T, Iversen K, Raaschou F, Schwartz M. Anticoagulants in acute myocardial infarction. Lancet. 1961;2(7198):327–31.
Carleton RA, Sanders CA, Burack WR. Heparin administration after acute myocardial infarction. N Engl J Med. 1960;263:1002–5.
Wasserman AJ, Gutterman LA, Yoe KB, Kemp Jr VE, Richardson DW. Anticoagulants in acute myocardial infarction: the failure of anticoagulants to alter mortality in a randomized series. Am Heart J. 1966;71(1):43–9.
Assessment of short-anticoagulant administration after cardiac infarction. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. Br Med J. 1969;1(5640):335–42.
Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction: relation of therapeutic benefit to patient’s age, sex, and severity of infarction. JAMA. 1972;222(5):541–8.
Handley AJ, Emerson PA, Fleming PR. Heparin in the prevention of deep vein thrombosis after myocardial infarction. Br Med J. 1972;2(5811):436–8.
Anticoagulants in acute myocardial infarction: results of a cooperative clinical trial. JAMA. 1973;225(7):724–9.
Leizorovicz A, Boissel JP. Oral anticoagulant in patients surviving myocardial infarction: a new approach to old data. Eur J Clin Pharmacol. 1983;24(3):333–6.
Sixty Plus Reinfarction Study Research Group. A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet. 1980;2(8202):989–94.
Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med. 1990;323(3):147–52.
Ferguson JJ. Meeting highlights: highlights of the 22nd Congress of the European Society of Cardiology. Circulation. 2001;103(8):E41–5.
Coumadin Aspirin Reinfarction Study (CARS) Investigators. Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet. 1997;350(9075):389–96.
Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study. Circulation. 2002;105(5):557–63.
Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41(4 Suppl S):62S–9.
Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation. 2004;110(8):904–10.
Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291(3):309–16.
Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43(8):1375–82.
Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Ranolazine Study Group. Am J Cardiol. 1999;84(1):46–50.
Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol. 2005;95(3):311–6.
Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775–83.
Cairns JA. Ranolazine: augmenting the antianginal armamentarium. J Am Coll Cardiol. 2006;48(3):576–8.
Stone PH, Gratsiansky NA, Blokhin A, Huang IZ, Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J Am Coll Cardiol. 2006;48(3):566–75.
Williams MA, Fleg JL, Ades PA, et al. Secondary prevention of coronary heart disease in the elderly (with emphasis on patients ≥75 years of age): an American Heart Association scientific statement from the Council on Clinical Cardiology Subcommittee on Exercise, Cardiac Rehabilitation, and Prevention. Circulation. 2002;105(14):1735–43.
Mamun AA, Peeters A, Barendregt J, et al. Smoking decreases the duration of life lived with and without cardiovascular disease: a life course analysis of the Framingham Heart Study. Eur Heart J. 2004;25(5):409–15.
Godtfredsen NS, Holst C, Prescott E, Vestbo J, Osler M. Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol. 2002;156(11):994–1001.
Sparrow D, Dawber TR. The influence of cigarette smoking on prognosis after a first myocardial infarction. A report from the Framingham study. J Chronic Dis. 1978;31(6–7):425–32.
World Health Organization. The world health report: reducing risks, promoting healthy life. Geneva: World Health Organization; 2002.
Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360(9349):1903–13.
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23):2981–97.
Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 2000;35(2):539–43.
Appel LJ, Moore TJ, Obarzanek E, et al. A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med. 1997;336(16):1117–24.
Willett WC, Sacks F, Trichopoulou A, et al. Mediterranean diet pyramid: a cultural model for healthy eating. Am J Clin Nutr. 1995;61(6 Suppl):1402S–6.
de Lorgeril M, Salen P, Martin JL, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999;99(6):779–85.
Knoops KT, de Groot LC, Kromhout D, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292(12):1433–9.
Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. JAMA. 2005;293(1):43–53.
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–9.
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335(14):1001–9.
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333(20):1301–7.
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504.
Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–80.
de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA. 2004;292(11):1307–16.
Pitt B, Waters D, Brown WV, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med. 1999;341(2):70–6.
Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.
Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406–15.
Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306(19):2099–109.
Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation. 2004;109(3):433–8.
Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111(11):1448–54.
Grundy SM, Hansen B, Smith Jr SC, Cleeman JI, Kahn RA. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management. Circulation. 2004;109(4):551–6.
Kereiakes DJ, Willerson JT. Metabolic syndrome epidemic. Circulation. 2003;108(13):1552–3.
Reilly MP, Rader DJ. The metabolic syndrome: more than the sum of its parts? Circulation. 2003;108(13):1546–51.
Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2005;48(9):1684–99.
Kantrowitz A. Experimental augmentation of coronary flow by retardation of the arterial pressure pulse. Surgery. 1953;34(4):678–87.
Singh M, Holmes Jr DR, Tajik AJ, Barsness GW. Noninvasive revascularization by enhanced external counterpulsation: a case study and literature review. Mayo Clin Proc. 2000;75(9):961–5.
Arora RR, Chou TM, Jain D, et al. The multicenter study of enhanced external counterpulsation (MUST-EECP): effect of EECP on exercise-induced myocardial ischemia and anginal episodes. J Am Coll Cardiol. 1999;33(7):1833–40.
Urano H, Ikeda H, Ueno T, et al. Enhanced external counterpulsation improves exercise tolerance, reduces exercise-induced myocardial ischemia and improves left ventricular diastolic filling in patients with coronary artery disease. J Am Coll Cardiol. 2001;37(1):93–9.
Arora RR, Lopez S, Saric M. Enhanced external counterpulsation improves systolic function by echocardiography in patients with coronary artery disease. Heart Lung. 2005;34(2):122–5.
Kern MJ, Aguirre FV, Tatineni S, et al. Enhanced coronary blood flow velocity during intraaortic balloon counterpulsation in critically ill patients. J Am Coll Cardiol. 1993;21(2):359–68.
Sessa WC, Pritchard K, Seyedi N, Wang J, Hintze TH. Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression. Circ Res. 1994;74(2):349–53.
Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA. 1995;273(3):199–208.
Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801–11.
Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280(7):605–13.
Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.
Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.
Hawkey CJ. COX-2 inhibitors. Lancet. 1999;353(9149):307–14.
Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–55.
FitzGerald GA. COX-2 and beyond: approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov. 2003;2(11):879–90.
Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520–8, 1522 p following 1528.
Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–102.
Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–80.
National Institutes of Health. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer’s disease prevention trial. http://www.nih.gov/news/pr/dec2004/od-20.htm. Accessed 23 July 2012.
Antman EM, DeMets D, Loscalzo J. Cyclooxygenase inhibition and cardiovascular risk. Circulation. 2005;112(5):759–70.
Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011;109(4):428–36.
Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860–70.
Borer JS, Bacharach SL, Green MV, et al. Real-time radionuclide cineangiography in the noninvasive evaluation of global and regional left ventricular function at rest and during exercise in patients with coronary-artery disease. N Engl J Med. 1977;296(15):839–44.
Corbett JR, Dehmer GJ, Lewis SE, et al. The prognostic value of submaximal exercise testing with radionuclide ventriculography before hospital discharge in patients with recent myocardial infarction. Circulation. 1981;64(3):535–44.
Willerson JT, Hillis LD, Buja LM, editors. Ischemic heart disease: clinical and pathological aspects. New York: Raven; 1982.
Willerson JT. Treatment of heart disease. New York: Gower Medical; 1993.
Hillis LD, Firth BG, Willerson JT. Manual of clinical problems in cardiology. 2nd ed. Boston: Little, Brown; 1984.
Packer M, Frishman WH. Calcium channel antagonists in cardiovascular disease: focus on Verapamil. East Norwalk: Appleton-Century Crofts; 1984.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer-Verlag London
About this chapter
Cite this chapter
Willerson, J.T., Ferguson, J.J., Patel, D.D. (2015). Medical Treatment of Stable Angina. In: Willerson, J., Holmes, Jr., D. (eds) Coronary Artery Disease. Cardiovascular Medicine. Springer, London. https://doi.org/10.1007/978-1-4471-2828-1_17
Download citation
DOI: https://doi.org/10.1007/978-1-4471-2828-1_17
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-4471-2827-4
Online ISBN: 978-1-4471-2828-1
eBook Packages: MedicineMedicine (R0)